Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17827625 | 0.64 | GPR3 (0.44) | CYP1A2 | |
| SCHEMBL13209355 | 0.63 | NOTUM (0.50) | NOTUMCYP1A2CYP2A6 | |
| SCHEMBL17827622 | 0.62 | GPR3 (0.43) | CYP1A2 | |
| SCHEMBL2608424 | 0.62 | GPR3 (0.52) | CYP1A2 | |
| SCHEMBL29625463 | 0.62 | GPR3 (0.52) | CYP1A2 | |
| SCHEMBL17680605 | 0.61 | GPR3 (0.41) | NOTUMCYP1A2CYP2A6 | |
| SCHEMBL18381750 | 0.60 | GPR3 (0.50) | CYP1A2 | |
| SCHEMBL22434649 | 0.60 | PSMB8 (0.41) | NOTUMCYP1A2CYP2A6 | |
| SCHEMBL21093081 | 0.60 | PTGER4 (0.41) | CYP1A2 | |
| SCHEMBL15128413 | 0.59 | GPR3 (0.42) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| CN-101298433-A | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy | BIOVITRUM AB (SE) | 2008-11-05 | — | — | CN | disclosed |
| CN-100378074-C | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2008-04-02 | — | — | CN | disclosed |
| US-7087750-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2006-08-08 | — | — | US | disclosed |
| CN-1714077-A | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2005-12-28 | — | — | CN | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1326830-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
| WO-2002032863-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | NOTUM 1567/4885CYP1A2 240/4885CYP2A6 94/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | NOTUM 1418/4885CYP1A2 220/4885CYP2A6 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.